OncoSec Medical Incorporated ONCS
At closeJun 23, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 1.65M
- Shares out
- 5.96M
- Forward P/E
- -0.57
- Volume
- 51.30M
- Open
- 0.3529
- Previous close
- 0.2772
- Day's range
- 0.252 – 0.3968
- Beta
- 2.00
- Analysts
- Hold
- Price target
- 110.00 (+39582.5%)
- Earnings date
- Jun 27, 2023
Key statistics
- Enterprise value
- 5.60M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.43M
- Total cash
- 3.68M
- Total debt
- 8.46M
- Return on equity
- -410.17%
- Short % of float
- 3.70%
- 50-day average
- 0.419703
- 200-day average
- 2.64
Analyst view
Consensus: hold
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Jun 27, 2023
Expected Jun 27, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 27, 2023 | Apr 1, 2023 | 0.00 | — | — | — |
| Mar 13, 2023 | Jan 1, 2023 | 0.00 | — | — | — |
| Dec 15, 2022 | Oct 1, 2022 | 0.00 | — | — | — |
| Oct 31, 2022 | Jul 1, 2022 | 0.00 | — | — | — |
| Jun 14, 2022 | Apr 1, 2022 | 0.00 | — | — | — |
| Mar 15, 2022 | Jan 1, 2022 | -2.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2022 | BTIG | down | Buy | Neutral |
| Mar 16, 2022 | BTIG | main | — | Buy |
| Mar 8, 2021 | BTIG | init | — | Buy |
| Nov 25, 2020 | Dawson James | init | — | Buy |
| Nov 25, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Nov 25, 2020 | H.C. Wainwright | main | Buy | Buy |
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oncosec.com
News
Why Is OncoSec Medical (ONCS) Stock Up 100% Today? 
Stocks That Hit 52-Week Lows On Thursday 
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why Is OncoSec Medical (ONCS) Stock Down 48% Today? 
3 Top Penny Stocks To Watch After Big News This Week - Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session 
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket 
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on ONCS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALPHA HOLDINGS, INC. | Unknown | Conversion of Exercise of derivative security | Feb 17, 2021 | 1,718,250 |
| BONSTEIN SARA M | Chief Operating Officer | Sale | Jan 15, 2020 | 41,389 |
| CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 15, 2021 | 0 |
| DALESANDRO MARGARET PH.D | Director | Purchase | Aug 22, 2021 | 20,000 |
| DELAVERSANO ROBERT J | Officer | Sale | Feb 8, 2023 | 1,008 |
| DEMESA JAMES M | Director | Stock Award(Grant) | Dec 16, 2018 | 22,501 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FNY Investment Advisers, LLC | 2.32% | 105,690 | 29.30K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 1.26% | 57,488 | 15.94K | Mar 30, 2023 |
| State Street Corporation | 0.55% | 25,187 | 6.98K | Mar 30, 2023 |
| Salzhauer, Michael | 0.46% | 20,799 | 5.76K | Mar 30, 2023 |
| Bank Of New York Mellon Corporation | 0.38% | 17,434 | 4.83K | Mar 30, 2023 |
| LPL Financial LLC | 0.38% | 17,404 | 4.82K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.25% | 7,517 | 2.08K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 1,003 | 278 | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.03% | 895 | 248 | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 706 | 195 | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 56 | 15 | Feb 27, 2023 |